The United States has confirmed 2,318 measles cases in 2026 as of July 23, according to CDC surveillance data, passing the 2,289 cases logged in all of 2025 and making this the country’s worst measles year since 1991. Five months of the year remain. At the same time, national MMR coverage among kindergartners has dropped to 92.5% for the 2024-25 school year, below the roughly 95% that public health agencies consider necessary to stop sustained spread.
Key takeaways
- The CDC counts 2,318 confirmed cases in 2026 so far, more than the 2,289 recorded in all of 2025, and the highest annual total in 35 years.
- Kindergarten MMR coverage is 92.5%, down from 95.2% in 2019-20 and under the roughly 95% threshold needed to block ongoing transmission.
- An outbreak along the Utah and Arizona border has been running for more than a year, which puts US measles elimination status on the agenda when the Pan American Health Organization meets in November 2026.
What happened
The case count is the headline number, but the vaccination number is what produced it. National kindergarten MMR coverage has fallen from 95.2% in 2019-20 to 92.5% in 2024-25. That looks like a small slide. It is not. Measles is one of the most contagious infections known, and the math of herd immunity is unforgiving near the top of the range. Below about 95%, chains of transmission that used to burn out instead keep going.
Coverage is also uneven. A 92.5% national average hides counties and school districts sitting far lower, and those pockets are where outbreaks start and stay.
The most consequential detail in the reporting from STAT News and CNN Health is not the total. It is the outbreak straddling the Utah and Arizona border, which has been active for more than a year. The US declared measles eliminated in 2000, and elimination is defined by the absence of continuous transmission of a single chain for 12 months or more. Once a chain crosses that line, the definition is no longer met. The Pan American Health Organization is scheduled to review the region in November 2026.
Dr. Kumar’s take
Here is the part that almost never makes the wire stories: measles is a neurological disease as much as a respiratory one.
Acute measles encephalitis, brain inflammation during or just after the infection, occurs in roughly 1 in 1,000 cases. Survivors can be left with seizures, deafness, or permanent cognitive impairment. As a neurosurgeon, I do not think of measles as a rash with a fever. I think of it as a virus with a documented route into the central nervous system.
Then there is subacute sclerosing panencephalitis, or SSPE. SSPE is a progressive brain degeneration that shows up years after the original infection, typically 7 to 10 years later, long after everyone has decided the child recovered fine. It starts with subtle personality and school changes, moves to myoclonic jerks, then to loss of motor control, and it is uniformly fatal. There is no cure. Risk is highest in children infected before age 2, exactly the group too young for the first MMR dose and therefore dependent on everyone around them being vaccinated.
So the misconception I would most like to retire is “measles is just a rash.” That belief is doing more work in the coverage gap than any argument about vaccine policy.
I would also push back on how the story is being framed. The 2,318 figure is dramatic and should be reported. But the number that determines whether the US keeps elimination status is the 12-month transmission clock on that Utah and Arizona chain, not the annual case count. A country can have a bad year and stay eliminated. It cannot have one chain running past 12 months and stay eliminated.
One caveat: confirmed case counts are provisional and get revised, and reporting tends to improve during a bad year, which can inflate the comparison against quieter ones. The vaccination trend is measured separately and is the more stable signal.
What it means for you
Check your family’s MMR status rather than assuming it. Two documented doses give about 97% protection against measles, and the standard schedule is one dose at 12 to 15 months and a second at 4 to 6 years.
If you are traveling internationally or into an active outbreak area with an infant, ask your pediatrician about an early dose. Infants as young as 6 months can be vaccinated in those situations, and the routine doses still follow later.
Adults who do not know their history can ask for a titer or simply get vaccinated again. There is no harm in an extra dose.
If you or your child develops fever with a rash, call ahead before walking into a clinic waiting room. The virus stays airborne in a room for up to two hours after an infected person leaves, and that is how a single case becomes a cluster.